Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Isothipendyl→

Isothipendyl Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
482-15-5
Molecular formula
C16H19N3S
Molecular weight
285.4 g/mol
Drug class
First-generation H1 antihistaminephenothiazine derivative
Mechanism of action
Competitively antagonises histamine H1 receptors, reducing histamine-mediated itching and allergic symptoms. It also has sedative and anticholinergic properties.
Indications / reported uses
  • Topical treatment of itching associated with allergic reactions and other local pruritic conditions, where authorised.

Sources: https://pubchem.ncbi.nlm.nih.gov/compound/3781 · https://www.ncbi.nlm.nih.gov/mesh/?term=C008214 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Isothipendyl Environmental Risk Assessment (ERA) (the Isothipendyl ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.